PuSH - Publication Server of Helmholtz Zentrum München

Müller, T.D. ; Blüher, M. ; Tschöp, M.H. ; DiMarchi, R.D.*

Anti-obesity drug discovery: Advances and challenges.

Nat. Rev. Drug Discov. 21, 201-223 (2022)
DOI PMC
Open Access Green as soon as Postprint is submitted to ZB.
Enormous progress has been made in the last half-century in the management of diseases closely integrated with excess body weight, such as hypertension, adult-onset diabetes and elevated cholesterol. However, the treatment of obesity itself has proven largely resistant to therapy, with anti-obesity medications (AOMs) often delivering insufficient efficacy and dubious safety. Here, we provide an overview of the history of AOM development, focusing on lessons learned and ongoing obstacles. Recent advances, including increased understanding of the molecular gut–brain communication, are inspiring the pursuit of next-generation AOMs that appear capable of safely achieving sizeable and sustained body weight loss.
Altmetric
Additional Metrics?
[➜Log in]
Edit extra informations Login
Publication type Article: Journal article
Document type Review
Corresponding Author
Keywords Glucagon-like Peptide-1; Diet-induced Obese; Growth-factor 21; Body-mass Index; Term Weight Control; Cardiovascular Risk-factors; Improves Glycemic Control; Semaglutide 2.4 Mg; Dependent Insulinotropic Polypeptide; Cannabinoid-1 Receptor Blocker
ISSN (print) / ISBN 1474-1776
Journal Nature Reviews - Drug Discovery
Quellenangaben Volume: 21, Issue: 3, Pages: 201-223 Article Number: , Supplement: ,
Publisher Nature Publishing Group
Publishing Place London
Non-patent literature Publications
Reviewing status Peer reviewed
Institute(s) Institute of Diabetes and Obesity (IDO)
Helmholtz Institute for Metabolism, Obesity and Vascular Research (HI-MAG)
Grants German Research Foundation
German Center for Diabetes Research (DZD e.V.)
European Research Council (ERC)
Alexander von Humboldt Foundation